Bradford A. Zakes

Chairman

Mr. Zakes has served as the company’s President and Chief Executive Officer since the inception of Cerevast Therapeutics in 2009. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent over 30 years in various segments of the pharmaceutical, biotechnology and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline) and ICOS Corporation. While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac and Serevent. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University and received his MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors and Executive Committee for the Biotechnology Industry Organization (BIO) as well as the Emerging Company Section Governing Body and the Standing Committees on International Affairs and Finance and Investment for BIO.

Yuquan Wang

Director

Mr. Wang is a Founding and Managing Partner of Haiyin Capital, a leading venture capital firm based in Beijing, China. Mr. Wang is an influential strategist and mentor of the venture capital industry in China. Mr. Wang is a recognized key opinion leader and global lecturer on the subject of healthcare, high-tech and social media. Prior to Haiyin Capital, Mr. Wang founded Consultech Pharma in 1995, which was acquired by Omnicom Group. Mr. Wang subsequently founded and served as the President of Frost & Sullivan’s management consulting division in Beijing. Mr. Wang is active on numerous corporate boards and continues to serve as the Chairman of Frost & Sullivan’s Beijing division. Mr. Wang graduated with honors from Beijing Normal University.

Xiaomei Wu

Director

Ms. Wu is a founding partner of Haiyin Capital. At Haiyin Capital, Ms. Wu leads all fund operational activities to include fundraising, LP relations, government relations and portfolio management. Prior to joining Haiyin, she held executive roles at Compaq China and served as Chairman & GM of Koanglian, GM of Junping Media, and GM of Capital Online. She earned her MBA from Concordia University in Wisconsin.